home · filing · 0001437749-22-013326
8-K filed May 24, 2022, 7:59 PM ET
ticker CRVO
CIK 0001053691
leadership
confidence high
sentiment neutral
materiality 0.50
Diffusion Pharmaceuticals appoints Raven Jaeger as Chief Regulatory Officer
CervoMed Inc.
Raven Jaeger, former SVP Regulatory Affairs at BridgeBio, named Chief Regulatory Officer effective May 18, 2022.
She brings 20 years regulatory experience, including leading team to first FDA approval at BridgeBio.
Compensation: $400k base salary, 35% target bonus, $60k sign-on bonus, 8,000 stock options vesting over 36 months.
She will oversee regulatory strategy for lead candidate TSC (trans sodium crocetinate) for hypoxic solid tumors.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
Raven Jaeger
Chief Regulatory Officer
Effective 2022-05-18
Filed May 24, 2022, 7:59 PM ET
On May 18, 2022, Raven Jaeger, M.S., was appointed as the Chief Regulatory Officer of Diffusion Pharmaceuticals Inc.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Raven Jaeger was appointed as Chief Regulatory Officer at CervoMed Inc..
Action appointed
Role Chief Regulatory Officer
Exact text from the filing
On May 18, 2022, Raven Jaeger, M.S., was appointed as the Chief Regulatory Officer of Diffusion Pharmaceuticals Inc.
View on SEC.gov
Source: SEC EDGAR
accession 0001437749-22-013326
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.